Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord upgrades Jupiter to 'hold' on cost-cutting, M&A moves

(Sharecast News) - Canaccord Genuity has raised its rating for Jupiter from 'sell' to 'hold', saying that the fund manager is taking actions to "right-size the business and rebuild scale". The broker has doubled its target price for the stock from 60p to 120p, hailing management's actions to cut costs and use surplus capital for attractive M&A.

"Material internal cost reductions were announced in May, delivering an average c.25% earnings uplift over FY25/26. The immediately accretive acquisition of CCLA was announced in July, which we estimate delivers 17% accretion pre-cost synergies and c.40% including fully realised cost synergies," Canaccord said in a research note.

However, prospects for organic revenue growth at Jupiter still remain "fragile and less within management's control", the broker said, highlighting the "active to passive shift" - investors are increasingly moving investments from actively managed funds to passively managed funds - and revenue margin compression as constant headwinds for the business.

"Jupiter reported 'rebuilding of momentum' in institutional flows but higher margin retail net outflows are yet to show improvement, meaningful and consistent evidence of which would make us more positive."

Jupiter's share were trading 1% higher at 125.2p by 1350 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.